Literature DB >> 12928478

Phenotypic effects of heterozygosity for a BRCA2 mutation.

Madhuri Warren1, Christopher J Lord, Julio Masabanda, Darren Griffin, Alan Ashworth.   

Abstract

Heterozygous carriers of mutations in the BRCA2 gene have a high risk of developing breast and other cancers. In these individuals, BRCA2 appears to act as a tumour suppressor gene, in that loss of the wild type allele is frequently observed within tumours, leading to loss of BRCA2 function. Because BRCA2 functions in DNA repair via homologous recombination, this leads to genomic instability. However, it is unclear whether loss of the wild type allele is stochastic or if heterozygosity for BRCA2 mutation carries a phenotype that contributes to tumorigenic progression. Here we demonstrate that, in a specific vertebrate cell type, the chicken B cell line DT40, heterozygosity for a BRCA2 mutation has a distinct phenotype. This is characterized by a reduced growth rate, increased cell death, heightened sensitivity to specific DNA damaging agents and reduced RAD51 focus formation after irradiation. Thus in certain cell types, genome instability might be driven directly by heterozygosity for BRCA2 mutation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12928478     DOI: 10.1093/hmg/ddg277

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  10 in total

1.  BRCA1 and BRCA2 in breast cancer predisposition and recombination control.

Authors:  Ralph Scully; Anyong Xie
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-07       Impact factor: 2.673

2.  The BRCA2-interacting protein BCCIP functions in RAD51 and BRCA2 focus formation and homologous recombinational repair.

Authors:  Huimei Lu; Xu Guo; Xiangbing Meng; Jingmei Liu; Chris Allen; Justin Wray; Jac A Nickoloff; Zhiyuan Shen
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

3.  BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.

Authors:  Britta Stordal; Kirsten Timms; Angela Farrelly; Danielle Gallagher; Steven Busschots; Mickaël Renaud; Julien Thery; Deborah Williams; Jennifer Potter; Thanh Tran; Greg Korpanty; Mattia Cremona; Mark Carey; Jie Li; Yang Li; Ozlem Aslan; John J O'Leary; Gordon B Mills; Bryan T Hennessy
Journal:  Mol Oncol       Date:  2013-01-31       Impact factor: 6.603

4.  Establishment of three human breast epithelial cell lines derived from carriers of the 999del5 BRCA2 Icelandic founder mutation.

Authors:  Agla J Rubner Fridriksdottir; Thorarinn Gudjonsson; Thorhallur Halldorsson; Johannes Björnsson; Margret Steinarsdottir; Oskar Thor Johannsson; Helga M Ogmundsdottir
Journal:  In Vitro Cell Dev Biol Anim       Date:  2005 Nov-Dec       Impact factor: 2.416

5.  Use of DNA-damaging agents and RNA pooling to assess expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients.

Authors:  Logan C Walker; Bryony A Thompson; Nic Waddell; Sean M Grimmond; Amanda B Spurdle
Journal:  PLoS Genet       Date:  2010-02-19       Impact factor: 5.917

Review 6.  Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights.

Authors:  Larry H Thompson; John M Hinz
Journal:  Mutat Res       Date:  2009-02-21       Impact factor: 2.433

7.  Restoration of CAPAN-1 cells with functional BRCA2 provides insight into the DNA repair activity of individuals who are heterozygous for BRCA2 mutations.

Authors:  Jeffrey T Holt; William P Toole; Vedang R Patel; HeeYoung Hwang; Erika T Brown
Journal:  Cancer Genet Cytogenet       Date:  2008-10-15

8.  Monoallelic characteristic-bearing heterozygous L1053X in BRCA2 gene among Sudanese women with breast cancer.

Authors:  Alsmawal A Elimam; Mohamed Elmogtba Mouaweia Mohamed Aabdein; Mohamed El-Fatih Moly Eldeen; Hisham N Altayb; Mohamed Adel Taha; Mohammed N Nimir; Mohamed D Dafaalla; Musaab M Alfaki; Mohamed A Abdelrahim; Abdelmohaymin A Abdalla; Musab I Mohammed; Mona Ellaithi; Muzamil Mahdi Abdel Hamid; Mohamed Ahmed Salih Hassan
Journal:  BMC Med Genet       Date:  2017-08-16       Impact factor: 2.103

9.  Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.

Authors:  Olafur Andri Stefansson; Jon Gunnlaugur Jonasson; Oskar Thor Johannsson; Kristrun Olafsdottir; Margret Steinarsdottir; Sigridur Valgeirsdottir; Jorunn Erla Eyfjord
Journal:  Breast Cancer Res       Date:  2009-07-09       Impact factor: 6.466

10.  DNA damage repair is unaffected by mimicked heterozygous levels of BRCA2 in HT-29 cells.

Authors:  Brian Tannenbaum; Tobechukwu Mofunanya; Alan R Schoenfeld
Journal:  Int J Biol Sci       Date:  2007-09-30       Impact factor: 6.580

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.